What disease is regorafenib used to treat?

Regorafenib (Regorafenib) is an oral multikinase inhibitor used to treat many types of advanced cancer. Its mechanism of action is through inhibition of multiple intracellular and extracellular protein kinases, including those involved in tumor angiogenesis, tumor cell proliferation, and maintenance of the tumor microenvironment. The following are the main indications for regorafenib :

1.Metastatic colorectal cancer (mCRC): Regorafenib (regorafenib) is approved for the treatment of patients with metastatic colorectal cancer who have failed standard treatments. Standard treatments include chemotherapy, anti-EGFR therapy (for KRAS wild-type tumors), and anti-VEGF therapy. Regorafenib provides a new treatment option in this setting, helping to control disease progression by inhibiting tumor angiogenesis and tumor cell proliferation pathways.

2.Gastrointestinal stromal tumor (GIST): Regorafenib (regorafenib) is an effective treatment option for patients with advanced or metastatic gastrointestinal stromal tumors who have failed imatinib and sunitinib. GIST is a rare gastrointestinal tumor. Regorafenib delays tumor progression by inhibiting multiple kinases related to tumor growth.

3.Hepatocellular carcinoma (HCC): Regorafenib (regorafenib) is approved for patients with hepatocellular carcinoma that has progressed after treatment with sorafenib. Hepatocellular carcinoma is the most common primary liver cancer and has limited treatment options. Regofenib (Regofenib)Provides a new treatment option through a multi-target inhibitory mechanism, helping to prolong the survival of patients.

Regorafenib 's multi-target mechanism allows it to show efficacy in a variety of cancer types. The kinases it targets include VEGFR1-3, TIE2, RAF-1, BRAF, KIT, RET et al., these kinases play important roles in tumor angiogenesis, tumor growth, and maintenance of the tumor microenvironment. By inhibiting these kinases, regorafenib can reduce the blood supply to tumors, inhibit tumor cell proliferation and survival, and ultimately delay disease progression.

In conclusion, Regorafenib is an effective treatment for a variety of advanced cancers, especially those whose disease has progressed despite standard treatments. Its multi-target inhibitory mechanism gives it unique advantages in cancer treatment and provides patients with more treatment options.